Loading...

Skip to main content

Call us on + 1 (800) 604-9114 for more information about our products

Looking for specific datasheet Manual/COA/MSDS?
Request a Manual/COA/MSDS

Interested to get a quote about our products?
Request a Quote

Testing Data

VEGFR-3/FLT-4, soluble Active Protein | VEGFR-3/FLT-4 active protein

Human VEGFR-3/FLT-4, soluble

Gene Names
FLT4; PCL; FLT41; LMPH1A; VEGFR3
Reactivity
Human
Purity
> 90% by SDS-PAGE & silver stain
Synonyms
VEGFR-3/FLT-4; soluble; Human VEGFR-3/FLT-4; Recombinant Human Soluble VEGFR-3/FLT-4-His; Vascular endothelial growth factor receptor 3; Fms-like tyrosine kinase 4; VEGFR-3/FLT-4 active protein
Ordering
For Research Use Only!
Host
Insect Cells
Reactivity
Human
Purity/Purification
> 90% by SDS-PAGE & silver stain
Form/Format
Lyophilized
Sequence
N-Terminal Sequence: DPSGYSMTPPTLNITEESHV
Sequence Length
757
N Terminal Sequence
DPSGYSMTPPTLNITEESHV
Buffer
PBS
Preparation and Storage
Lyophilized samples are stable for greater than six months at -20 degree C to -70 degree C. Reconstituted sVEGFR-3/FLT-4 should be stored in working aliquots at -20 degree C. Avoid repeated freeze-thaw cycles!

Testing Data

Testing Data
Related Product Information for VEGFR-3/FLT-4 active protein
Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.
Product Categories/Family for VEGFR-3/FLT-4 active protein
References
1. Joukov et al., EMBO J 15 :290, 1996 2. Kukk et al., Development 122 :3829, 1996

NCBI and Uniprot Product Information

NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Accession #
Molecular Weight
110 kDa (Monomer)
NCBI Official Full Name
vascular endothelial growth factor receptor 3 isoform 2
NCBI Official Synonym Full Names
fms-related tyrosine kinase 4
NCBI Official Symbol
FLT4
NCBI Official Synonym Symbols
PCL; FLT41; LMPH1A; VEGFR3
NCBI Protein Information
vascular endothelial growth factor receptor 3; FLT-4; VEGFR-3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; fms-like tyrosine kinase 4; tyrosine-protein kinase receptor FLT4
UniProt Protein Name
Vascular endothelial growth factor receptor 3
UniProt Gene Name
FLT4
UniProt Synonym Gene Names
VEGFR3; VEGFR-3; FLT-4
UniProt Entry Name
VGFR3_HUMAN

NCBI Description

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008]

Uniprot Description

Function: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'. Ref.5 Ref.14 Ref.15 Ref.16 Ref.18 Ref.19 Ref.20 Ref.22 Ref.23 Ref.24 Ref.25 Ref.27 Ref.28 Ref.29 Ref.30

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Ref.13 Ref.17

Enzyme regulation: Present in an inactive conformation in the absence of bound ligand. Binding of VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by MAZ51. Ref.19 Ref.24 Ref.27

Subunit structure: Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-2. Identified in a complex with SRC and ITGB1. Ref.5 Ref.6 Ref.14 Ref.15 Ref.17 Ref.18 Ref.19 Ref.20 Ref.22 Ref.25 Ref.26 Ref.27 Ref.28

Subcellular location: Cell membrane; Single-pass type I membrane protein Ref.6 Ref.13 Ref.22 Ref.29. Cytoplasm Ref.6 Ref.13 Ref.22 Ref.29. Nucleus. Note: Ligand-mediated autophosphorylation leads to rapid internalization. Ref.6 Ref.13 Ref.22 Ref.29Isoform 1: Cell membrane; Single-pass type I membrane protein Ref.6 Ref.13 Ref.22 Ref.29. Note: Ligand-mediated autophosphorylation leads to rapid internalization. Ref.6 Ref.13 Ref.22 Ref.29Isoform 2: Cell membrane; Single-pass type I membrane protein Ref.6 Ref.13 Ref.22 Ref.29. Isoform 3: Secreted. Cytoplasm Ref.6 Ref.13 Ref.22 Ref.29.

Tissue specificity: Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney. Ref.1 Ref.14 Ref.28

Domain: The first and second Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFC binding.

Post-translational modification: Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H2O2 is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC at Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337. Ref.5 Ref.14 Ref.15 Ref.17 Ref.18 Ref.19 Ref.20 Ref.24 Ref.27

Involvement in disease: Lymphedema, hereditary, 1A (LMPH1A) [MIM:153100]: A chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.17 Ref.19 Ref.35 Ref.36 Ref.37Hemangioma, capillary infantile (HCI) [MIM:602089]: A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.38Plays an important role in tumor lymphangiogenesis, in cancer cell survival, migration, and formation of metastases.

Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 7 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.

Sequence caution: The sequence CAA48290.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.

Research Articles on VEGFR-3/FLT-4

Similar Products

Product Notes

The VEGFR-3/FLT-4 flt4 (Catalog #AAA691970) is an Active Protein produced from Insect Cells and is intended for research purposes only. The product is available for immediate purchase. The Human VEGFR-3/FLT-4, soluble reacts with Human and may cross-react with other species as described in the data sheet. The amino acid sequence is listed below: N-Terminal Sequence: DPSGYSMTPP TLNITEESHV. It is sometimes possible for the material contained within the vial of "VEGFR-3/FLT-4, soluble, Active Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.

Precautions

All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.

Disclaimer

Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.

Item has been added to Shopping Cart

If you are ready to order, navigate to Shopping Cart and get ready to checkout.

Looking for a specific manual?
Request a Manual

Request more Information

Please complete the form below and a representative will contact you as soon as possible.

Request a Manual

Please complete the form below and a representative will contact you as soon as possible.

Request a Quote

Please complete the form below and a representative will contact you as soon as possible.